{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:22:55Z","timestamp":1790634175479,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T00:00:00Z","timestamp":1351641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study set out to examine in a large real\u2010life cohort of patients with chronic myeloid leukemia (CML) the impact of imatinib threshold of 1000\u00a0ng\/mL on molecular response, as suggested in a small subset of patients. Patient plasma samples were submitted from around France to a central facility, free of charge under the auspices of the European Treatment and Outcome Study (EUTOS) for CML. Submitting physicians were required to complete an \u2018imatinib monitoring request form\u2019, including details of why therapeutic drug monitoring (TDM) was requested, dose and duration of imatinib treatment, cytogenetic and molecular response, adverse events, and concurrent medications. Imatinib trough plasma concentration (<jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub>) was measured at the central facility. Among 1985 eligible plasma samples analyzed, from 1216 CML patients, imatinib <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> correlated positively with reported imatinib dose, but interpatient variability in <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> was high (60%). A logistic regression analysis revealed that treatment duration and imatinib <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub>\u00a0&gt;\u00a01000\u00a0ng\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content> were significantly associated with major and complete molecular responses with odds ratios of 1.69 and 2.08, respectively. These data support in real\u2010life setting that imatinib <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> threshold of 1000\u00a0ng\/mL is associated with major and complete molecular response and that TDM could play an important role in dose optimization.<\/jats:p>","DOI":"10.1111\/fcp.12007","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T03:56:47Z","timestamp":1351742207000},"page":"690-697","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory"],"prefix":"10.1111","volume":"27","author":[{"given":"St\u00e9phane","family":"Bouchet","sequence":"first","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"},{"name":"INSERM U657 F\u201033000 Bordeaux France"},{"name":"CHU Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Titier","sequence":"additional","affiliation":[{"name":"CHU Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"},{"name":"INSERM U657 F\u201033000 Bordeaux France"},{"name":"CHU Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Lassalle","sequence":"additional","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Ambrosino","sequence":"additional","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Poulette","sequence":"additional","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schuld","sequence":"additional","affiliation":[{"name":"Novartis Pharma SpA Origgio Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Belanger","sequence":"additional","affiliation":[{"name":"Novartis Pharma SA Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois\u2010Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"},{"name":"CHU Bordeaux F\u201033000 Bordeaux France"},{"name":"INSERM U1035 F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[{"name":"Univ Bordeaux F\u201033000 Bordeaux France"},{"name":"INSERM U657 F\u201033000 Bordeaux France"},{"name":"CHU Bordeaux F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,31]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_5_3_1","first-page":"447","article-title":"Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS])","volume":"112","author":"Guilhot F.","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.186"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.88"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.02.023"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000175973.71140.91"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.10.001"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373902"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.07.015"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181b2c8cf"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0b013e3182263ac4","article-title":"Use of total and unbound imatinib and metabolite LC\u2010MS\/MS assay to understand individual responses in CML and GIST patients","volume":"33","author":"Streit F.","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"e_1_2_5_18_1","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen M.H.","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.4"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00301.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-079871"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2010.00849.x"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12007","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:48:18Z","timestamp":1696301298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,31]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/fcp.12007"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12007","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,31]]},"assertion":[{"value":"2012-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}